Hollern, Daniel P.
Contreras, Cristina M.
Dance-Barnes, Stephanie
Silva, Grace O.
Pfefferle, Adam D.
Xiong, Jessie
Darr, David B.
Usary, Jerry
Mott, Kevin R.
Perou, Charles M. http://orcid.org/0000-0001-9827-2247
Funding for this research was provided by:
National Cancer Institute (F32-CA210427, P50-CA58223, RO1-CA148761, RO1-CA195740)
Susan G Komen (SAC-160074, KG091395)
Breast Cancer Research Foundation
Article History
Received: 9 November 2018
Accepted: 16 November 2018
First Online: 27 November 2018
Compliance with ethical standards
:
: C.M.P is an equity stock holder and Board of Director Member of BioClassifier, LLC, and GeneCentric Diagnostics. C.M.P is also listed as an inventor on patent applications on the Breast PAM50. G.O.S is an employee and stock holder of Blueprint Medicines Corporation.
: All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. This article does not contain any studies with human participants performed by any of the authors.